WealthPlan Investment Management LLC Acquires New Position in Gilead Sciences, Inc. $GILD

WealthPlan Investment Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,106 shares of the biopharmaceutical company’s stock, valued at approximately $344,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Brighton Jones LLC raised its stake in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new stake in Gilead Sciences in the 4th quarter valued at about $215,000. GAMMA Investing LLC raised its stake in Gilead Sciences by 24.9% in the 1st quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after acquiring an additional 4,532 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in Gilead Sciences by 4.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company’s stock valued at $32,827,000 after acquiring an additional 13,194 shares during the period. Finally, Premier Path Wealth Partners LLC raised its stake in Gilead Sciences by 10.1% in the 1st quarter. Premier Path Wealth Partners LLC now owns 8,864 shares of the biopharmaceutical company’s stock valued at $993,000 after acquiring an additional 812 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.65.

Gilead Sciences Stock Up 4.2%

Shares of NASDAQ GILD opened at $122.81 on Friday. Gilead Sciences, Inc. has a 12 month low of $85.60 and a 12 month high of $124.11. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $152.38 billion, a price-to-earnings ratio of 24.46, a PEG ratio of 0.81 and a beta of 0.34. The business has a 50-day moving average of $115.22 and a 200-day moving average of $110.53.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,500 shares of company stock valued at $8,281,540. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.